In this study, a signature consisting of 10 PRGs (BAK1, BAX, CASP1, CASP4, CASP6, GSDME, GZMA, GZMB, IL18, and TP53) was selected based on the PRGs reported in the literature (Karki and Kanneganti 2019; Man and Kanneganti 2015; Xia et al. 2019; Ye et al. 2021), which has the capability to predict the survival of HCC patients. This evidence concerns the gene TP53 and hepatocellular carcinoma.